Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes

Diabetes Care

Volumn 36, Issue 8, 2013, Pages 2346-2350

  Ceriello, Antonio ^a   Novials, Anna ^a   Ortega, Emilio ^a   Canivell, Silvia ^a   La Sala, Lucia ^a   Pujadas, Gemma ^a   Esposito, Katherine ^b   Giugliano, Dario ^b   Genovese, Stefano ^c  

^a HOSPITAL CLÍNIC   (Spain)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c IRCCS MULTIMEDICA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; 8 ISOPROSTAGLANDIN F2 ALPHA; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; GLUCOSE BLOOD LEVEL;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INDICATION; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METABOLIC REGULATION; OXIDATIVE STRESS; RISK FACTOR; YOUNG ADULT; BLOOD; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; ENDOTHELIUM, VASCULAR; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; MALE; OXIDATIVE STRESS;

EID: 84879783953     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-2469     Document Type: Article

References (28)

1. Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor? Diabetes Metab Res Rev 2008;24: 353-363
2. Singh P, Jain A, Kaur G. Impact of hypoglycemia and diabetes on CNS: correlation of mitochondrial oxidative stress with DNA damage. Mol Cell Biochem 2004; 260:153-159
3. Wright RJ, Newby DE, Stirling D, Ludlam CA,Macdonald IA, Frier BM. Effects of acute insulin-induced hypoglycemia on indices of inflammation: putative mechanism for aggravating vascular disease in diabetes. Diabetes Care 2010;33:1591-1597
4. Gogitidze Joy N, Hedrington MS, Briscoe VJ, Tate DB, Ertl AC, Davis SN. Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals. Diabetes Care 2010;33: 1529-1535
5. Wang J, Alexanian A, Ying R, et al. Acute exposure to low glucose rapidly induces endothelial dysfunction and mitochondrial oxidative stress: role for AMP kinase. Arterioscler Thromb Vasc Biol 2012;32: 712-720
6. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010;107:1058-1070
7. Ceriello A. Hyperglycaemia and the vessel wall: the pathophysiological aspects on the atherosclerotic burden in patients with diabetes. Eur J Cardiovasc Prev Rehabil 2010;17(Suppl 1):S15-S19
8. Razavi Nematollahi L, Kitabchi AE, Stentz FB, et al. Proinflammatory cytokines in response to insulin-induced hypoglycemic stress in healthy subjects [corrected in Metabolism 2009;58:1046]. Metabolism 2009;58:443-448
9. Nandish S, Wyatt J, Bailon O, Smith M, Oliveros R, Chilton R. Implementing cardiovascular risk reduction in patients with cardiovascular disease and diabetes mellitus. Am J Cardiol 2011;108(Suppl): 42B-51B
10. Peters A. Incretin-based therapies: review of current clinical trial data. Am J Med 2010;123(Suppl):S28-S37
11. Meier JJ, Nauck MA. Is the diminished incretin effect in type 2 diabetes just an epiphenomenon of impaired beta-cell function? Diabetes 2010;59:1117-1125
12. Issa CM, Azar ST. Possible role of GLP-1 and its agonists in the treatment of type 1 diabetesmellitus. Curr Diab Rep 2012;12: 560-567
13. Mudaliar S, Henry RR. Effects of incretin hormones on beta-cell mass and function, body weight, and hepatic and myocardial function. Am J Med 2010;123(Suppl): S19-S27
14. Nyström T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287:E1209-E1215
15. Ceriello A, Esposito K, Testa R, Bonfigli AR, Marra M, Giugliano D. The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an "endothelial resistance" to glucagon-like peptide 1 in diabetes. Diabetes Care 2011;34:697-702
16. Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Silljé HH. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol 2010;30:1407-1414
17. Ewing DJ, Martyn CN, Young RJ, Clarke BF. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care 1985;8:491-498
18. Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care 1994; 17:697-703
19. Amiel SA, Tamborlane WV, Simonson DC, Sherwin RS. Defective glucose counterregulation after strict glycemic control of insulin-dependent diabetes mellitus. N Engl J Med 1987;316:1376-1383
20. Nauck MA,HeimesaatMM,Orskov C, Holst JJ, Ebert R,Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993;91: 301-307
21. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223
22. Ceriello A, Mercuri F, Quagliaro L, et al. Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia 2001;44:834-838
23. Ceriello A, Esposito K, Ihnat M, Thorpe J, Giugliano D. Effect of acute hyperglycaemia, long-term glycaemic control and insulin on endothelial dysfunction and inflammation in Type 1 diabetic patients with different characteristics. Diabet Med 2010;27:911-917
24. Monnier L, Colette C, Mas E, et al. Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia 2010;53:562-571
25. Orchard TJ, Costacou T.When are type 1 diabetic patients at risk for cardiovascular disease? Curr Diab Rep 2010;10:48-54 [PubMed]
26. Costacou T, Ferrell RE, Orchard TJ. Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes. Diabetes 2008;57:1702-1706
27. Costacou T, Zgibor JC, Evans RW, Tyurina YY, Kagan VE, Orchard TJ. Antioxidants and coronary artery disease among individuals with type 1 diabetes: Findings from the Pittsburgh Epidemiology of Diabetes Complications Study. J Diabetes Complications 2006;20:387-394
28. Ceriello A, Novials A, Ortega E, et al. Evidence that hyperglycemia after recovery from hypoglycemia worsens endothelial function and increases oxidative stress and inflammation in healthy control subjects and subjects with type 1 diabetes. Diabetes 2012;61:2993-2997